Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat
International Journal of Neuropsychopharmacology · 2024
DOI: 10.1093/ijnp/pyae066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Ryan T Terry-Lorenzo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neurocrine Biosciences, Inc., San Diego, CA, United States. Hauptthemen laut MEDLINE: Schizophrenia, D-Amino-Acid Oxidase, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Neurocrine Biosciences.
Abstract (Originalsprache)
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been proposed to underlie the pathophysiology of schizophrenia, suggesting that promoting NMDAR activity may alleviate the negative or cognitive symptoms associated with schizophrenia. To circumvent excitotoxicity that may accompany direct agonism of the glutamate binding site on the NMDAR, therapeutic trials have focused on targeting the glycine binding site on the NMDAR. Direct administration of either glycine or D-serine, both of which are endogenous coagonists at the NMDAR glycine site, has yielded mixed outcomes across an array of clinical trials investigating different doses or patient populations. Furthermore, directly administering D-serine and glycine is challenging, and thus attention has turned to alternative, indirect methods that increase endogenous D-serine and glycine levels in the brain, such as D-amino acid oxidase (DAAO) inhibitors and glycine transporter 1 inhibitors, respectively. In this review, we provide an overview of the evidence supporting the potential of NMDAR modulators in general, and DAAO inhibitors in particular, as potential adjunctive treatments for schizophrenia. We also discuss the preclinical and clinical data related to luvadaxistat, an investigational highly selective and potent DAAO inhibitor that was under development for the treatment of the cognitive impairment associated with schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurocrine Biosciences, Inc., San Diego, CA, United States.
ORCID-Profile: Ryan T Terry-Lorenzo, Reuben H Fan, Ni A Khin, Jaskaran B Singh
Förderung
- Neurocrine Biosciences
Zitieren
APA
Terry-Lorenzo, R. T., Fan, R. H., Khin, N. A., & Singh, J. B. (2024). Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae066
Vancouver
Terry-Lorenzo RT, Fan RH, Khin NA, Singh JB. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyae066
BibTeX
@article{TerryLorenzo2024,
author = {Terry-Lorenzo, Ryan T and Fan, Reuben H and Khin, Ni A and Singh, Jaskaran B},
title = {Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat},
journal = {International Journal of Neuropsychopharmacology},
year = {2024},
doi = {10.1093/ijnp/pyae066}
}
EUVIMED